Tirzepatide by quarter
Coverage and results for Tirzepatide quarter by quarter. Read the supplier-count column beside the median: a quarter where the compound mix changed is not comparable with the one before it, and the index cannot hold that constant retrospectively.
| Quarter | Batches | Reports | Median purity % | IQR pp | Suppliers | Flagged | What changed in the index |
|---|---|---|---|---|---|---|---|
| 2024-Q1 | 5 | 30 | 98.70 | 1.15 | 4 | 30 | Backfill quarter. Reports assayed earlier were accepted retrospectively where custody could be documented. |
| 2024-Q2 | 7 | 36 | 98.07 | 1.02 | 5 | 36 | First quarter of live submission. |
| 2024-Q3 | 6 | 23 | 98.27 | 0.75 | 6 | 23 | Nordanalyt Laboratories began contributing. |
| 2024-Q4 | 5 | 26 | 97.91 | 1.42 | 4 | 25 | Impurity-fingerprint matching introduced; first shared-bulk links published. |
| 2025-Q1 | 9 | 68 | 99.28 | 0.87 | 6 | 65 | Anomaly rule set expanded from seven rules to eleven. |
| 2025-Q2 | 10 | 66 | 98.39 | 0.89 | 10 | 63 | Gravimetric mass-balance reconciliation became mandatory on new records. |
| 2025-Q3 | 14 | 66 | 98.16 | 1.02 | 10 | 66 | Kestrel Bioanalytical began contributing; gradient-length normalisation introduced. |
| 2025-Q4 | 12 | 65 | 98.76 | 1.20 | 8 | 65 | Provenance classification became a required field. |
| 2026-Q1 | 11 | 66 | 98.37 | 1.06 | 9 | 65 | Rule AX-R12 added. Dataset v2 schema published. |
| 2026-Q2 | 13 | 93 | 98.39 | 1.17 | 11 | 88 | Buyer-sourced sensitivity analysis added to every supplier scorecard. |
| 2026-Q3 | 4 | 37 | 98.37 | 2.01 | 4 | 37 | Quarter in progress. Aggregates for this quarter are provisional. |
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes. A trend across 11 points, most of them thin, is a shape and not a finding.